Macular Degeneration Clinical Trial
Official title:
Correlation Between Reading Specific New Visual Acuity Measurement Methods, Patient Self-reported Quality of Life Assessments, Macular Morphological Parameters and Standardized Study Protocol ETDRS Visual Acuity in Wet AMD Patients
Patient-reported vision-related quality of life (QOL) outcomes are increasingly incorporated
into clinical trials of new treatments for age-related macular degeneration (AMD). In
patients with central visual field defects they often do not correlate with distance visual
acuity changes as evaluated according to the Early Treatment Diabetic Retinopathy Study
(ETDRS) protocol. Therefore there is the need for better correlated visual acuity (VA)
outcome measures for these patients. In a current big trial for treatment of dry AMD
(geographic atrophy) reading speed and low luminance visual acuity are used as outcome
measures for the first time. However, limited information is available regarding the
associations between distance ETDRS visual acuity, reading speed, low luminance visual
acuity, contrast sensitivity, morphological parameters and the National Eye Institute Visual
Function Questionnaire-25 (NEI VFQ-25) subscales judged relevant to these measures.
Evaluating these correlations could provide the basis for objective study outcome parameters
which are better correlated to patient-reported outcomes. Further it increases the
understanding of the impact of visual impairment on activities and functioning in patients
with eye diseases.
There is an immediate benefit to the study patients, as they might gain information regarding
their individual results regarding objective VA measures, contrast sensitivity (and their
impact on reading ability). Furthermore, the results of the study could be beneficial for
future patients due to, e.g., a better understanding of the disease, especially regarding
factors which have an impact on their near vision ability and therefore their quality of
life. The study could provide a basis to find and include outcome measures which are
correlated better with quality of life than ETDRS distance VA for further AMD trials.
3.1 Background and Rationale AGE-RELATED MACULAR Degeneration (AMD) is the leading cause of
blindness among European descended people older than 65 years.
Today, the average life expectancy in developed nations is over 80 years and climbing. And
yet, the quality of life during those additional years is often significantly diminished by
the effects of age-related, degenerative diseases, including age-related macular degeneration
(AMD) Central-field loss (CFL) is often a consequence of macular degeneration, necessitating
the use of peripheral vision for reading That means that AMD affects the central vision,
resulting in central scotomas and therefore the patients have problems with near distance
activities like reading while the peripheral visual field is kept preserved.
AMD is a gradually progressive disease that evolves through stages into severe central vision
loss. The earliest signs of AMD involve the appearance of extracellular deposits (drusen),
sub-retinal deposits of oxidized lipids and proteins beneath the retinal pigment epithelium
(RPE), and variable amounts of visible clumps of pigment in the macula. In the intermediate
stages of AMD, drusen become larger and pigmentary changes are more severe. In the advanced
stages, patients develop either sub-retinal choroidal neovascularization (the exudative or
"wet" form of AMD) or the non-neovascular "dry" form of AMD. The dry form of AMD is
characterized by sharply demarcated uni- or multi-focal regions of dysfunctional macula,
termed geographic atrophy (GA). The GA patches gradually enlarge to involve the RPE and the
corresponding neurosensory retina and choriocapillaris layer of the choroid. These
progressive and irreversible changes ultimately cause permanent loss of central (macular)
vision.
Geographic atrophy (GA) may cause significant compromise of visual function, even when there
still is good visual acuity (VA), because of parafoveal scotomas and foveal function
abnormalities antedating visible atrophy AMD is a multifactorial disease with largely unknown
pathophysiology. It is believed to be caused by cumulative damage over a lifetime leading to
progressive deterioration of the RPE, Bruch's membrane and Choriocapillaris-choroid complex
(key players in maintaining retinal function), followed by photoreceptor cells damage.
However, the locus of primary damage still remains unclear. Identified pathogenic mechanisms
to date include a range of genetic and environmental factors related to primary RPE
senescence, oxidative stress, alterations in the complement pathway, increased inflammation,
changes in the balance of growth factors, and excessive lipofuscin accumulation. Areas of GA
are associated with absolute scotomas. Thus, for a period of years, many patients with GA
have good VA because of foveal preservation but are limited by the scotomas surrounding the
fovea. For example, a patient may have VA of 20/40 or better, but be unable to fit more than
a few letters of a word or a full face in the seeing foveal region .Often multiple central
scotomas with very small islands of preserved VA, allow the patient to read single optotypes
but not the whole word Visual acuity is the most widely used measure of macular function in
clinical trials and clinical practice. However, reading ability is an important component of
vision function. Reading difficulty diminishes quality of life . Improvement in reading
performance is one of the main objectives for elderly low-vision patients ETDRS often does
not reflect the reading problems of the patient which are essential in daily life. High
contrast distance acuity is not the only relevant measure of visual function in relation to
the perceived visual performance of a patient with macular disease (Hazel et al. 2000).
The visual impairment experienced by many patients with age-related macular degeneration
(AMD) has been found to affect their ability to perform usual activities, which cause
psychological distress, and limit their participation in social events. PROs of visual
function provide a more comprehensive evaluation of the impact of, and the effects of
treatment for AMD Progression of dry AMD can be slowed in many patients through dietary
supplements while visual loss from wet AMD is treated with intravitreal administration of
anti-vascular growth factor Therefore there is the need to find a better outcome parameter.
The primary purpose of the study will be to evaluate if there is a correlation between
self-reported reading difficulties and new near vision testing instrument results and
secondarily to establish how strong self-reported reading difficulties are-correlated to
functional and morphological parameters. To also evaluate how strong the standard distance
visual acuity measurements (ETDRS) are correlated to further functional and morphological
parameters.
The study could provide a basis to find and include outcome measures which are correlated
better with quality of life than ETDRS distance VA for further AMD trials.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
Completed |
NCT02540954 -
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
|
Phase 3 | |
Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
Completed |
NCT02510794 -
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT02228304 -
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02181504 -
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
|
Phase 2 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01204541 -
A Single-Center Pilot Study to Assess Macular Function
|
N/A | |
Completed |
NCT00769392 -
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
|
N/A | |
Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
Completed |
NCT00536016 -
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
|
Phase 1 | |
Withdrawn |
NCT00538538 -
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
|
Phase 1 | |
Terminated |
NCT00403442 -
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
|
Phase 1 | |
Recruiting |
NCT00157976 -
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT00239928 -
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
Completed |
NCT00211458 -
Treatment of Age-Related Macular Degeneration With Anecortave Acetate
|
Phase 2 | |
Completed |
NCT00095433 -
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
|
Phase 3 | |
Completed |
NCT00006202 -
Lutein for Age-Related Macular Degeneration
|
Phase 2 |